Clinical Trial: A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged >= 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR).

U.S., May 31 -- ClinicalTrials.gov registry received information related to the study (NCT06997159) titled 'A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged >= 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR).' on May 13.

Brief Summary: The purpose of this clinical trial is to measure efficacy, safety and pharmacokinetics (PK) of two LXE408 oral regimens and oral miltefosine tablets as active control in localized cutaneous leishmaniasis in the region of the Americas (AMR), and assess its suitability for use in monotherapy for the treatment of patients with cutaneous leishmaniasis (CL).

St...